Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | HTR3A | P46098 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.41 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.39 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5026209 | 0.83 | SMN1; SMN2 (0.48) | SMN1; SMN2HTR1AHTR3ACA12CA1 | |
| SCHEMBL8425831 | 0.81 | CYP1A2 (0.47) | SMN1; SMN2HTR1AHTR3ACA12CA1 | |
| SCHEMBL2059269 | 0.80 | CA1 (0.55) | HTR1AHTR3ACA12CA1CA2 | |
| SCHEMBL8425830 | 0.79 | SMN1; SMN2 (0.45) | SMN1; SMN2HTR1AHTR3ACA12CA1 | |
| SCHEMBL25434306 | 0.77 | CA1 (0.61) | SMN1; SMN2CA12CA1CA2CA4 | |
| SCHEMBL151213 | 0.77 | CA1 (0.61) | SMN1; SMN2CA12CA1CA2CA4 | |
| SCHEMBL27753904 | 0.77 | CA1 (0.61) | SMN1; SMN2CA12CA1CA2CA4 | |
| SCHEMBL7056347 | 0.76 | SMN1; SMN2 (0.42) | SMN1; SMN2HTR1AHTR3ACA12CA1 | |
| SCHEMBL19982800 | 0.75 | SMN1; SMN2 (0.41) | SMN1; SMN2HTR1AHTR3ACA12CA1 | |
| SCHEMBL9109781 | 0.75 | SMN1; SMN2 (0.46) | SMN1; SMN2HTR1AHTR3ACA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6989263-B1 | Method for identifying and using compounds that inactivate HIV-1 and other retroviruses by attacking highly conserved zinc fingers in the viral nucleocapsid protein | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-01-24 | — | — | US | claimed |
| US-20030198648-A1 | Methods for identifying compounds which inhibit binding of nucleocapsid 7 protein to HIV-1 RNA | ACHILION PHARMACEUTICALS | 2003-10-23 | — | — | US | claimed |
| WO-2003060098-A2 | METHODS FOR IDENTIFYING COMPOUNDS WHICH INHIBIT BINDING OF NUCLEOCAPSID 7 PROTEIN TO HIV-1 RNA | ACHILLION PHARMACEUTICALS, INC. (US) | 2003-07-24 | — | — | WO | claimed |
| EP-0782632-B1 | A METHOD FOR IDENTIFYING AND USING COMPOUNDS THAT INACTIVATE HIV-1 AND OTHER RETROVIRUSES BY ATTACKING HIGHLY CONSERVED ZINC FINGERS IN THE VIRAL NUCLEOCAPSID PROTEIN | US GOV HEALTH & HUMAN SERV (US) | 2003-04-16 | — | — | EP | claimed |
| US-6001555-A | DISSOCIATING A ZINC FINGER BY CONTACTING THE PROTEIN WITH A DISULFIDE, A MALEIMIDE, AN ALPHA-HALOGENATED KETONE, A HYDRAZIDE, A NITRIC OXIDE OR DERIVATIVES, CUPRIC IONS, FERRIC IONS OR THEIR COMPLEXES; SYNERGISTIC EFFECTS WITH VIRICIDES | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-12-14 | — | — | US | claimed |
| EP-0782632-A1 | A METHOD FOR IDENTIFYING AND USING COMPOUNDS THAT INACTIVATE HIV-1 AND OTHER RETROVIRUSES BY ATTACKING HIGHLY CONSERVED ZINC FINGERS IN THE VIRAL NUCLEOCAPSID PROTEIN | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the Secretary of the Department of Health and Human Services (US) | 1997-07-09 | — | — | EP | claimed |
| WO-1996009406-A9 | A METHOD FOR IDENTIFYING AND USING COMPOUNDS THAT INACTIVATE HIV-1 AND OTHER RETROVIRUSES BY ATTACKING HIGHLY CONSERVED ZINC FINGERS IN THE VIRAL NUCLEOCAPSID PROTEIN | — | 1996-05-23 | — | — | WO | claimed |
| WO-1996009406-A1 | A METHOD FOR IDENTIFYING AND USING COMPOUNDS THAT INACTIVATE HIV-1 AND OTHER RETROVIRUSES BY ATTACKING HIGHLY CONSERVED ZINC FINGERS IN THE VIRAL NUCLEOCAPSID PROTEIN | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-03-28 | — | — | WO | claimed |
| US-20160160178-A1 | IMMUNOTHERAPY USING STEM CELLS | WHITE OAK IND INC (US) | 2016-06-09 | — | — | US | disclosed |
| US-20150125489-A1 | METHOD FOR THE PREPARATION OF DENDRITIC CELL VACCINES | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2015-05-07 | — | — | US | disclosed |
| EP-2819696-A1 | METHOD FOR THE PREPARATION OF DENDRITIC CELL VACCINES | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2015-01-07 | — | — | EP | disclosed |
| WO-2013127976-A1 | METHOD FOR THE PREPARATION OF DENDRITIC CELL VACCINES | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2013-09-06 | — | — | WO | disclosed |
| EP-1011729-B1 | OLIGONUCLEOTIDES WHICH SPECIFICALLY BIND RETROVIRAL NUCLEOCAPSID PROTEINS | US GOV HEALTH & HUMAN SERV (US) | 2008-01-09 | — | — | EP | disclosed |
| US-7101676-B2 | Methods for identifying compounds which inhibit binding of nucleocapsid 7 protein to HIV-1 RNA | ACHILION PHARMACEUTICALS | 2006-09-05 | — | — | US | disclosed |
| EP-0960096-A1 | SUBSTITUTED $g(b)-THIOCARBOXYLIC ACIDS | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1999-12-01 | — | — | EP | disclosed |
| WO-1998032734-A1 | SUBSTITUTED β-THIOCARBOXYLIC ACIDS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-07-30 | — | — | WO | disclosed |
| WO-1997044064-A2 | OLIGONUCLEOTIDES WHICH SPECIFICALLY BIND RETROVIRAL NUCLEOCAPSID PROTEINS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-11-27 | — | — | WO | disclosed |
| EP-0782632-A1 | A METHOD FOR IDENTIFYING AND USING COMPOUNDS THAT INACTIVATE HIV-1 AND OTHER RETROVIRUSES BY ATTACKING HIGHLY CONSERVED ZINC FINGERS IN THE VIRAL NUCLEOCAPSID PROTEIN | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the Secretary of the Department of Health and Human Services (US) | 1997-07-09 | — | — | EP | disclosed |
| WO-1996009406-A9 | A METHOD FOR IDENTIFYING AND USING COMPOUNDS THAT INACTIVATE HIV-1 AND OTHER RETROVIRUSES BY ATTACKING HIGHLY CONSERVED ZINC FINGERS IN THE VIRAL NUCLEOCAPSID PROTEIN | — | 1996-05-23 | — | — | WO | disclosed |
| WO-1996009406-A1 | A METHOD FOR IDENTIFYING AND USING COMPOUNDS THAT INACTIVATE HIV-1 AND OTHER RETROVIRUSES BY ATTACKING HIGHLY CONSERVED ZINC FINGERS IN THE VIRAL NUCLEOCAPSID PROTEIN | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160160178-A1 | IMMUNOTHERAPY USING STEM CELLS | CD14, ICOS, BMP4 | SMN1; SMN2 2370/4885HTR1A 2899/4885HTR3A 1120/4885 |
| US-20150125489-A1 | METHOD FOR THE PREPARATION OF DENDRITIC CELL VACCINES | CCR7, CD69, CD14 | SMN1; SMN2 2803/4885HTR1A 4881/4885HTR3A 4831/4885 |
| US-20030198648-A1 | Methods for identifying compounds which inhibit binding of nucleocapsid 7 protein to HIV-1 RNA | MRPS27, SNRPE, NSUN2 | SMN1; SMN2 3061/4885HTR1A 3866/4885HTR3A 3262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.